Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic

Leonardo M. R. FerreiraMohammed A. Mostajo-Radji2026-03-222026-03-22202010.31235/osf.io/cyqx8https://doi.org/10.31235/osf.io/cyqx8https://andeanlibrary.org/handle/123456789/84058Convalescent plasma therapy holds promise as a transient treatment for COVID-19. Yet, blood products are important sources of HIV infection in low- and middle-income nations. Great care must be taken to prevent plasma therapy from fueling HIV epidemics in the developing world.enCoronavirus disease 2019 (COVID-19)Low and middle income countriesHuman immunodeficiency virus (HIV)MedicineVirology2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicLow incomeDeveloping countryPlasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemicpreprint